Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 355 first-in-human study in advanced solid tumors
NL-OMON59118Phase 1Completed
- Sponsor
- Amgen
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of FPA157 and pembrolizumab in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC) and 1 more (2 arms), sponsored by Amgen. Started Jul 2024; status: completed.
02
Drugs
FPA157pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)gastric cancer (GC)melanoma
Beyond the preview
Go deeper on NL-OMON59118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59118.